Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3714195 | 0.91 | — | — | |
| SCHEMBL957862 | 0.91 | AR (0.38) | ARDDR1CA12CA9ALDH1A1 | |
| SCHEMBL12180420 | 0.91 | AR (0.35) | ARDDR1CA12CA9 | |
| SCHEMBL1663166 | 0.89 | AR (0.36) | ARDDR1CA12CA9 | |
| SCHEMBL1660919 | 0.88 | CA12 (0.35) | ARDDR1CA12CA9ALDH1A1 | |
| SCHEMBL1661310 | 0.87 | AR (0.35) | ARDDR1CA12CA9ALDH1A1 | |
| SCHEMBL3714197 | 0.87 | — | — | |
| SCHEMBL3714200 | 0.87 | ALDH1A1 (0.32) | ALDH1A1POLBHTTHSD17B10 | |
| SCHEMBL1661036 | 0.87 | CA12 (0.35) | ARDDR1CA12CA9 | |
| SCHEMBL15184766 | 0.87 | CA12 (0.35) | ARDDR1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | claimed |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | ALLGEIER HANS (DE) | 2014-01-16 | — | — | US | claimed |
| EP-2585070-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | Novartis AG (CH) | 2013-05-01 | — | — | EP | claimed |
| US-20130096145-A1 | Use of 1H-quinazoline-2,4-diones | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | claimed |
| US-20130090346-A1 | Use of 1H-quinazoline-2,4-diones | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | claimed |
| WO-2013036224-A1 | USE OF 1H-QUINAZOLINE- 2, 4 -DIONES FOR USE IN THE PREVENTION OR TREATMENT PHOTOSENSITIVE EPILEPSY | NOVARTIS AG (CH) | 2013-03-14 | — | — | WO | claimed |
| EP-2490691-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | Novartis AG (CH) | 2012-08-29 | — | — | EP | claimed |
| US-20120122903-A1 | 1-H-QUINAZOLINE-2, 4-DIONES FOR USE IN THE TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| WO-2011161249-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2011-12-29 | — | — | WO | claimed |
| WO-2011048150-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | claimed |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | ALLGEIER HANS (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | ALLGEIER HANS (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| EP-1871749-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108591-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090346-A1 | Use of 1H-quinazoline-2,4-diones | GRIK2, GRIK1, GRIK4 | AR 4646/4885DDR1 1011/4885CA12 2397/4885 |
| US-20130096145-A1 | Use of 1H-quinazoline-2,4-diones | GRM1, GRIK2, GRIK1 | AR 4467/4885DDR1 2209/4885CA12 3842/4885 |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | GRIK1, GRIK2, GRIK4 | AR 4495/4885DDR1 1095/4885CA12 720/4885 |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | GRIK2, GRIK1, GRIK4 | AR 4646/4885DDR1 1011/4885CA12 2397/4885 |
| US-20120122903-A1 | 1-H-QUINAZOLINE-2, 4-DIONES FOR USE IN THE TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | CLN6, GBA1, GBA2 | AR 4852/4885DDR1 2239/4885CA12 4310/4885 |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | GRIN2A, GRIN1, GRIN2D | AR 2441/4885DDR1 3161/4885CA12 3261/4885 |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | AR 3874/4885DDR1 2722/4885CA12 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.